Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

Addressing barriers in acute myeloid leukaemia care in India to improve outcomes and survival rates for patients.

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

Objective Bone marrow-derived myeloid cells accumulate in the liver as monocytes and macrophages during the progression of obesity-related non-alcoholic fatty liver disease (NAFLD) to steatohepatitis ...

In SLE, there is evidence of deregulation of haematopoiesis with skewing towards the myeloid lineage at the expense of lymphopoiesis and priming of HSPCs that exhibit a ‘trained immunity’ signature; ...

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

Chronic myeloid (or myelogenous ... enables leukemic stem cells to escape immune surveillance and supports disease growth.

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

Our findings show that local GM-CSF therapy during PVM disease increased local neutrophilia and monocyte-derived cell influx, but diminished CD8 + T cells responses. Despite this, the observed effects ...

Federal funding enables biomedical engineer Jamie Spangler and her team to develop innovative treatments for autoimmune ...